MX2023000902A - Combinacion farmaceutica de temozolomida e inhibidor de la enzima mutante idh1. - Google Patents
Combinacion farmaceutica de temozolomida e inhibidor de la enzima mutante idh1.Info
- Publication number
- MX2023000902A MX2023000902A MX2023000902A MX2023000902A MX2023000902A MX 2023000902 A MX2023000902 A MX 2023000902A MX 2023000902 A MX2023000902 A MX 2023000902A MX 2023000902 A MX2023000902 A MX 2023000902A MX 2023000902 A MX2023000902 A MX 2023000902A
- Authority
- MX
- Mexico
- Prior art keywords
- temozolomide
- inhibitor
- combination drug
- mutated idh1
- idh1 enzyme
- Prior art date
Links
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004964 temozolomide Drugs 0.000 title abstract 3
- 229940000425 combination drug Drugs 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 206010064571 Gene mutation Diseases 0.000 abstract 1
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 101150046722 idh1 gene Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Al combinar temozolomida con un inhibidor de la enzima mutante IDH1, se descubrió que la dosis de temozolomida podía reducirse sin disminuir el efecto antitumoral, lo que nos permitió brindar un fármaco combinado con excelente eficacia contra los cánceres con mutaciones en IDH1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020124331 | 2020-07-21 | ||
PCT/JP2021/027070 WO2022019289A1 (ja) | 2020-07-21 | 2021-07-20 | テモゾロミドと変異型idh1酵素阻害剤の組み合わせ医薬 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023000902A true MX2023000902A (es) | 2023-02-22 |
Family
ID=79728790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023000902A MX2023000902A (es) | 2020-07-21 | 2021-07-20 | Combinacion farmaceutica de temozolomida e inhibidor de la enzima mutante idh1. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230270814A1 (es) |
EP (1) | EP4186525A4 (es) |
JP (1) | JP2022021331A (es) |
KR (1) | KR20230042065A (es) |
CN (1) | CN116348145A (es) |
AU (1) | AU2021311539A1 (es) |
BR (1) | BR112022026634A2 (es) |
CA (1) | CA3189348A1 (es) |
CO (1) | CO2023001045A2 (es) |
IL (1) | IL299859A (es) |
MX (1) | MX2023000902A (es) |
TW (1) | TW202216139A (es) |
WO (1) | WO2022019289A1 (es) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102827170A (zh) * | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
ES2665619T3 (es) | 2013-03-14 | 2018-04-26 | Novartis Ag | 3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
PE20170143A1 (es) * | 2014-02-11 | 2017-03-19 | Bayer Pharma AG | Benzimidazol-2-aminas como inhibidores de midh1 |
ES2706525T3 (es) | 2014-09-19 | 2019-03-29 | Forma Therapeutics Inc | Derivados de piridinilquinolinona como inhibidores de isocitrato deshidrogenasa mutante |
CN106795146B (zh) * | 2014-10-01 | 2020-06-26 | 第一三共株式会社 | 作为突变型异柠檬酸脱氢酶1抑制剂的异噁唑衍生物 |
TW201708193A (zh) | 2015-07-27 | 2017-03-01 | 拜耳製藥公司 | 突變之異檸檬酸脫氫酶idh1 r132h之抑制劑 |
BR112019026435A2 (pt) * | 2017-06-12 | 2020-07-14 | Agios Pharmaceuticals, Inc. | métodos de tratamento de tumores cerebrais usando terapia de combinação |
JP2019094299A (ja) * | 2017-11-22 | 2019-06-20 | 第一三共株式会社 | アルキル化剤抵抗性のがんの治療剤 |
-
2021
- 2021-07-20 IL IL299859A patent/IL299859A/en unknown
- 2021-07-20 JP JP2021119216A patent/JP2022021331A/ja active Pending
- 2021-07-20 AU AU2021311539A patent/AU2021311539A1/en active Pending
- 2021-07-20 KR KR1020237005800A patent/KR20230042065A/ko unknown
- 2021-07-20 US US18/016,540 patent/US20230270814A1/en active Pending
- 2021-07-20 TW TW110126529A patent/TW202216139A/zh unknown
- 2021-07-20 MX MX2023000902A patent/MX2023000902A/es unknown
- 2021-07-20 EP EP21845205.0A patent/EP4186525A4/en active Pending
- 2021-07-20 BR BR112022026634A patent/BR112022026634A2/pt unknown
- 2021-07-20 CN CN202180060294.5A patent/CN116348145A/zh active Pending
- 2021-07-20 CA CA3189348A patent/CA3189348A1/en active Pending
- 2021-07-20 WO PCT/JP2021/027070 patent/WO2022019289A1/ja unknown
-
2023
- 2023-01-31 CO CONC2023/0001045A patent/CO2023001045A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20230270814A1 (en) | 2023-08-31 |
BR112022026634A2 (pt) | 2023-01-31 |
CO2023001045A2 (es) | 2023-02-06 |
CN116348145A (zh) | 2023-06-27 |
KR20230042065A (ko) | 2023-03-27 |
AU2021311539A1 (en) | 2023-02-09 |
EP4186525A4 (en) | 2024-04-03 |
WO2022019289A1 (ja) | 2022-01-27 |
CA3189348A1 (en) | 2022-01-27 |
EP4186525A1 (en) | 2023-05-31 |
IL299859A (en) | 2023-03-01 |
TW202216139A (zh) | 2022-05-01 |
JP2022021331A (ja) | 2022-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
MX2021013218A (es) | Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2. | |
JOP20220083A1 (ar) | حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr | |
MX2022002465A (es) | Inhibidores de kras g12d. | |
CL2018000955A1 (es) | Terapia de combinación para el tratamiento de neoplasias malignas | |
PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
MX2021013788A (es) | Dosificación del inhibidor de kras para el tratamiento de cánceres. | |
MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
CA3156451A1 (en) | ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES | |
MX2018010261A (es) | Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. | |
MX2018004586A (es) | Terapia de combinacion para tratar tumores malignos. | |
MX2018009750A (es) | Composiciones potenciadoras de vcn y métodos para su uso. | |
MX2018013413A (es) | Compuestos inhibidores de egfr. | |
ZA201803162B (en) | Combination therapy for treating malignancies | |
MX2019010149A (es) | Inhibicion del smarca2 para el tratamiento del cancer. | |
MX2023000549A (es) | Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr. | |
MX2022010975A (es) | Inhibidores de egfr, kras, braf y otras dianas y uso de estos. | |
MX2019002108A (es) | Terapia de combinacion con inhibidores de glutaminasa. | |
PH12017501741A1 (en) | Histamine-producing bacterial strains and their use in cancer | |
CR20240059A (es) | Compuestos tricíclicos como inhibidores de kras. | |
GB2568000A (en) | Compositions and methods for treating cancer with arginine depletion and immuno oncology agents | |
WO2023287730A8 (en) | Tricyclic compounds | |
MX2023011294A (es) | Combinacion de talazoparib y un antiandrogeno para el tratamiento del cancer de prostata sensible a la castracion metastasico mutado en el gen ddr. | |
MX2022000811A (es) | Inhibidores de enzimas. | |
MX2019006552A (es) | Terapia génica para mucopolisacaridosis de tipo i. |